Clinical Trials
5 trialsNCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT05969184 2023-08-01
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05577442 2022-10-19
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05244993 2022-07-12
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05075512 2021-10-12
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Recruiting